Sort   by:  
 Page size 
UnknownNet clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Not available
S-EPMC3816957 | biostudies-literature
UnknownWhole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?
Not available
S-EPMC6075843 | biostudies-literature
UnknownClinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor.
Not available
S-EPMC3595426 | biostudies-literature
UnknownPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Not available
S-EPMC3577951 | biostudies-literature
UnknownPhase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Not available
S-EPMC3157965 | biostudies-literature
UnknownBEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.
Not available
S-EPMC4669379 | biostudies-literature
UnknownOutcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
Not available
S-EPMC5773840 | biostudies-literature
UnknownImpact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
Not available
S-EPMC6269130 | biostudies-literature
UnknownPhase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.
Not available
S-EPMC6075856 | biostudies-literature
UnknownCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Not available
S-EPMC4226803 | biostudies-literature
Sort   by:  
 Page size